Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade-Reference-Cited by-同舟云学术

Glucocorticoid Receptor Confers Resistance to Antiandrogens by Bypassing Androgen Receptor Blockade

Published:2013-12 Issue:6 Volume:155 Page:1309-1322
ISSN:0092-8674
Container-title:Cell
language:en
Short-container-title:Cell

Author:

Arora Vivek K.,Schenkein Emily,Murali Rajmohan,Subudhi Sumit K.,Wongvipat John,Balbas Minna D.,Shah Neel,Cai Ling,Efstathiou Eleni,Logothetis Chris,Zheng Deyou,Sawyers Charles L.

Publisher

Elsevier BV

Subject

General Biochemistry, Genetics and Molecular Biology

Reference33 articles.

1. Overcoming mutation-based resistance to antiandrogens with rational drug design;Balbas;eLife,2013

2. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N. Engl. J. Med.,2011

3. Molecular determinants of resistance to antiandrogen therapy;Chen;Nat. Med.,2004

4. ARN-509: a novel antiandrogen for prostate cancer treatment;Clegg;Cancer Res.,2012

5. Association of glucocorticoid receptors with prostate nuclear sites for androgen receptors and with androgen response elements;Davies;J. Mol. Endocrinol.,1990

Cited by 807 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. PLXNA1 confers enzalutamide resistance in prostate cancer via AKT signaling pathway;Neoplasia;2024-11

2. Un-methylation of NUDT21 represses docosahexaenoic acid biosynthesis contributing to enzalutamide resistance in prostate cancer;Drug Resistance Updates;2024-11

3. Current uses and resistance mechanisms of enzalutamide in prostate cancer treatment;Expert Review of Anticancer Therapy;2024-09-14

4. Targeting Androgen, Thyroid Hormone, and Vitamin A and D Receptors to Treat Prostate Cancer;International Journal of Molecular Sciences;2024-08-26

5. Bioinformatics analysis reveals that CBX2 promotes enzalutamide resistance in prostate cancer;European Journal of Medical Research;2024-08-22